Compare ARKO & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARKO | AURA |
|---|---|---|
| Founded | 1970 | 2007 |
| Country | United States | United States |
| Employees | 9748 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 737.0M | 713.4M |
| IPO Year | N/A | 2021 |
| Metric | ARKO | AURA |
|---|---|---|
| Price | $8.65 | $6.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.50 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 782.1K | 448.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.86 | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | $56.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $4.73 |
| 52 Week High | $8.68 | $9.54 |
| Indicator | ARKO | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 74.89 | 35.73 |
| Support Level | $7.32 | $5.81 |
| Resistance Level | N/A | $6.56 |
| Average True Range (ATR) | 0.32 | 0.34 |
| MACD | 0.06 | -0.13 |
| Stochastic Oscillator | 92.33 | 19.95 |
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. It derives the majority of its revenue from retail and wholesale distribution of fuel.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.